附近上门

The drug discovery pipeline can take, on average, a decade to get from the lab to the patient. aims to speed up the innovation of cell and gene therapies via the manufacturing platform it is bringing to market.

Subscribe to the 附近上门 Daily

The London and Woodcliff Lake, New Jersey-based company is developing a platform that closes, automates and standardizes manufacturing for cell and gene therapy developers so they can move their treatments from the pre-clinical process through to scale commercially.

鈥淭hese products are super expensive to manufacture, and even with the biggest good manufacturing practices in place, you couldn鈥檛 do beyond a few thousand doses,鈥� , Ph.D., co-founder and chief scientific officer at Ori Biotech, told 附近上门 News. 鈥淲e are using our novel automation to reduce the cost of goods and the footprint. Producing hundreds of thousands of doses per year is impossible right now, but with Ori you will be able to do it.”

Helping the company get its platform on the market is a new $30 million Series A round of funding led by , with participation from and Ori鈥檚 existing institutional investors: , and . The new funding gives Ori Biotech a total of $40 million in funding since its inception in 2015, including a $10 million seed round in 2018, Veraitch said.

In addition to taking the platform to the market, estimated to be in late 2021 or early 2022, the company expects to double its employee count in the next four months and double that again by next year. Currently, the company has eight employees, including its first two in the U.S.

The company has been working with external partners over the past four months doing testing. One partner is already getting good results from testing the platform on its treatment for solid tumors, Ori Biotech鈥檚 CEO said in an interview.

鈥淲e are hoping to grow our external partnerships from three to six in the next year,鈥� Foster added.

Meanwhile, the company is addressing a $9 billion market that has 1,500 gene therapy clinical trials going on in cancer, diabetes and rare diseases. There are approximately eight approved products, and most are in pre-clinical or Phase 1 testing, he said.

, co-founder and partner at Northpond Ventures, said in an interview that Veraitch is 鈥渙bsessed鈥� with how cell and gene therapies need to be brought to market.

Northpond looked at a lot of companies in this space, and thought the Ori Biotech team and modular approach was differentiated and had the opportunity to change how these therapies are made.

鈥淔arlan and Jason are phenomenal humans doing critical work,鈥� she said. 鈥淕lobally speaking, the health care system is broken, and the cost of developing drugs is outpacing the ability to pay for them. Now you can treat someone on a personalized basis without the cost burden, and Ori has a chance to be that solution.鈥�

Illustration: